Comparison of the efficacy and safety of two kinds of mixed protamine Zinc recombinant human insulin lispro injection (50R) in the treatment of diabetes: a multicenter, randomized, parallel, positive controlled clinical trial
张献博,边芳,王海芳,刘丽君,李波,符文燕,刘婕,苏秀海,史华民,戴武,刘长梅,李枢,逄曙光,胡文,邵挥戈,肖建中,董其娟,李进,叶山东,孙清元,孙丽,王昆,刘瑞云,袁慧娟,孙凤娟,杜瑞琴,陈立波,李子玲,王东济,楼雪勇,李清波,李洪梅,李建薇,王淑萍,杨涛,王肃,郭立新
DOI: https://doi.org/10.3760/cma.j.cn115791-20211231-00698
2022-01-01
Abstract:Objective:To compare the efficacy and safety of Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R) (WANBANG) and Humalog Mix 50 (Lilly) in the treatment of type 2 diabetes mellitus (T2DM).Methods:A multicenter, randomized, parallel, positive control, phase Ⅲ clinical trial was conducted. From August 30, 2018 to May 27, 2020, 612 patients with T2DM with poor glycemic control by oral hypoglycemic agents were enrolled from 36 centers nationwide, and were followed random number method assigned to the experimental group (WANBANG) and the control group (Lilly) according to 1∶1 for 16 weeks. The glycated hemoglobin A 1c (HbA 1c), fasting plasma glucose (FPG), 2-hour postprandial glucose (2hPG), body weight, blood lipid, HbA 1c compliance rate at the end, the incidence of hypoglycemic events and adverse events and the positive rate of insulin antibody were compared between the two groups before and after treatment. Results:Of the 612 patients, 609 were included in the safety data set, including 305 in the experimental group and 304 in the control group; 534 cases were enrolled into the protocol set, including 267 cases in the experimental group and 267 cases in the control group. After 16 weeks of treatment, HbA 1c decreased by 1.85%±1.23% and 1.90%±1.27%, respectively. FPG decreased by (3.56±2.99) and (3.72±3.26) mmol/L, 2hPG decreased by (6.94±5.41) and (7.07±5.10) mmol/L, respectively, there was no significant difference in the above indexes between the two groups ( P>0.05). There was no significant difference in the overall incidence of hypoglycemia [51.15% (156/305) vs. 45.72% (139/304)], the incidence of adverse events [76.39% (233/305) vs. 77.63% (236/304)] and the positive conversion rate of insulin antibody [22.85% (61/267) vs. 19.10% (51/267)] between the experimental group and Humalog Mix 50 group ( P>0.05). Conclusions:The efficacy and safety of Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection 50R (WANBANG) in treating T2DM is similar to that of Humalog Mix 50, and is well tolerated. This study has positive significance for reducing the medical burden of the country.